Kincell Bio Appoints Mark R. Bamforth as Chief Executive Officer
Mark R. Bamforth, CEO, Kincell Bio・ Photo Credit: Kincell Bio
Corporate Business News Sponsored by Business Watch Global
RESEARCH TRIANGLE PARK, N.C., January 20, 2025 (VSNewsNetwork.com) — Cell therapy development and manufacturing company Kincell Bio has announced the appointment of Mark R. Bamforth as Chief Executive Officer (CEO). Bamforth has been Chair of the Board since May 2024 and will now oversee the company’s operations and growth efforts in the cell therapy sector.
Bamforth has over two decades of experience in the biopharmaceutical industry. He founded and served as CEO of three Contract Development and Manufacturing Organizations (CDMO): Arranta Bio, Brammer Bio, and Gallus Bio. He also worked at Genzyme Corp. for 22 years, where he led global operations for multiple therapeutic areas. His experience includes managing manufacturing operations, building partnerships, and delivering solutions for clients in the biopharmaceutical field.
“I look forward to building on the solid foundation that Bruce has established and working more deeply with him and the talented team at Kincell Bio to expand our cell therapy CDMO business to meet the development, clinical, and commercial launch needs of clients from innovative biotechs to Fortune 500-backed companies that are developing solutions to address critical unmet needs for patients,” said Bamforth.
Bruce Thompson, PhD, Chief Technology Officer, said, “I am excited to partner with Mark to strengthen the technical development capabilities at Kincell Bio. We have built a strong team and will now be better positioned to meet the cell therapy needs of clients. We are committed to expanding our process and analytical development capabilities through internal development and partnerships with technology and solution providers, to solve the challenges of scale, complexity, and performance in the cell therapy sector.”
@VSNewsNetwork
•
@VSNewsNetwork •
Kincell Bio provides process and analytical development, cGMP manufacturing, and support for early and late-stage clinical programs. The company focuses on cell therapy products, including CAR-T, CAR-NK, and stem cell therapies.
For more information, visit www.kincellbio.com.
Source: Kincell Bio
